Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FY 2021 Appropriations Provides FDA Healthy Boost – Plus More COVID-19 Funds

Executive Summary

Budget authority increase for medical product safety is coupled with additional funds for coronavirus countermeasure development and advanced manufacturing.

You may also be interested in...



Biden Vaccination Plan Would Grow Domestic Manufacturing Base

Proposal, which would increase capacity for pandemic supplies, is similar to ideas President Trump embraced pre-pandemic.

Expanded Distribution For COVID Vaccines Will Boost Options – And Logistical Complications

Operation Warp Speed officials eye the Moderna vaccine and upcoming one-shot Janssen product to widen the immunization campaign’s reach, but more products also could bring more problems.

PDUFA VII: US FDA Wants Dedicated RMAT Program Funding

Cell and gene therapy product activities also have increased CBER’s workload significantly and strained staff, the agency tells industry representatives.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM006922

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel